ArticleJournal of thoracic disease2025
Real-time magnetic resonance imaging guided accelerator in stereotactic body radiation therapy for non-small cell lung cancer.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Detection and localization of radiation-induced pneumonitis usingPhysics and imaging in radiation oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stereotactic body radiotherapy (SBRT) is crucial for lung tumor treatment, but facing challenges like intra-fractional anatomical changes and organ risks. Magnetic resonance-guided online adaptive SBRT (MRg-SBRT) is an innovative technique promising safer delivery of ablative doses and protect organ at risk (OAR). This study aimed to investigate the feasibility of the whole process of MRg-SBRT for non-small cell lung cancer (NSCLC) patients. Methods: Physical parameters of radiotherapy for 23 cases of NSCLC who underwent MRg-SBRT were retrospectively analyzed. This included patients' treatment course, planned target volume (PTV), target area coverage, and OAR recipient volume. The focus was on inter- and intra-fraction MR real-time monitoring to correct off-target. Local control and adverse event outcomes of patients' SBRT treatment were also retrospectively analyzed. Results: All 23 patients completed treatment on time without any treatment interruptions or pauses due to the MR. Tumor movement was predominantly in the superior-inferior (SI) directions through Elekta Unity real-time online monitoring. The baseline plan was altered in four patients, and an adaptive plan was used to correct inter- and intra-fraction off-targeting in a timely manner. The prescribed dose coverage for PTV was 95.3%, with a median bilateral lung volume 20 (V20) GY of 6.3%, and a maximal dose to the spinal cord of 117.3 cGy. The response results showed that the disease control rate (DCR) was 100% with an objective response rate (ORR) of 82.6%. Follow-up results showed an acute grade one to two pneumonia incidence of 82.6% and grade three pneumonias in one patient. Conclusions: MRg-SBRT can guide treatment plans for the clinical needs of SBRT for lung cancer patients, especially for old patients, proving the feasibility of SBRT for lung lesions with MRg-SBRT, and online real-time monitoring reduces intra- and inter-fraction off-targeting, and guarantees the treatment efficiency of patients without significantly increasing the incidence of serious adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.